Coming Soon – May 2019 Dyslipidemia is an important modifiable risk factor...
Coming Soon – May 2019 Dyslipidemia is an important modifiable risk factor for cardiovascular disease, which is one of the leading causes of death globally. Statin...
Current treatment of type 1 diabetes (T1D) consists only of exogenous insulins...
Current treatment of type 1 diabetes (T1D) consists only of exogenous insulins and Symlin, with Lantus as the patient-share leader in the United States. Intensive insulin regimens have been shown......
A wide array of drugs are available to treat osteoporosis. These drugs are...
A wide array of drugs are available to treat osteoporosis. These drugs are generally effective in reducing patients’ risk of fracture and are well tolerated. Oral bisphosphonates, espe...
Gout is a chronic condition characterized by intermittent acute flares caused...
Gout is a chronic condition characterized by intermittent acute flares caused by elevated serum uric acid (sUA). Treatment of the painful acute flares is distinct from the chronic management of h......
Market Outlook Because no current therapy for type 2 diabetes offers disease...
Market Outlook Because no current therapy for type 2 diabetes offers disease-modifying capabilities, a high unmet need exists for drugs that can effectively control...
The type 2 diabetes therapy market will steadily expand over our 2017-2027...
The type 2 diabetes therapy market will steadily expand over our 2017-2027 study period, fueled by increasing prevalence and high unmet need for drugs that can effectively control the diseas...
Patients with osteoporosis are at increased risk of suffering fractures due to...
Patients with osteoporosis are at increased risk of suffering fractures due to a loss in bone strength. These fractures, in turn, place a considerable burden on public health systems. The osteopo......
Dyslipidemia refers to abnormalities in the composition, concentration, or...
Dyslipidemia refers to abnormalities in the composition, concentration, or size of lipids and lipoproteins in the circulation, and it is a key modifiable risk factor for cardiovascular (...
Overall, the renal anemia therapy market will expand over the 2017-2027 study...
Overall, the renal anemia therapy market will expand over the 2017-2027 study period, fueled by the increasing prevalence of this complication of chronic kidney disease and the emergence of a nov......
MARKET OUTLOOK Biguanides and sulfonylureas are by far the most heavily...
MARKET OUTLOOK Biguanides and sulfonylureas are by far the most heavily prescribed type 2 diabetes (T2D) drug classes. However, seve......
MARKET OUTLOOK Obesity is arguably the most pressing public health issue in...
MARKET OUTLOOK Obesity is arguably the most pressing public health issue in the United States. The prevalence of obesity is extremely high, and its chronic progression i......
Dyslipidemia refers to abnormalities in lipids and lipoproteins in the...
Dyslipidemia refers to abnormalities in lipids and lipoproteins in the circulation and is a key modifiable risk factor for cardiovascular (CV) disease. The mos......
Dyslipidemia is a key modifiable risk factor for cardiovascular (CV) disease....
Dyslipidemia is a key modifiable risk factor for cardiovascular (CV) disease. Current lipid-modifying therapies, including statins, ezetimibe, fibrates, omega-......
Amyloidosis is caused by the deposition of insoluble amyloid fibrils formed by...
Amyloidosis is caused by the deposition of insoluble amyloid fibrils formed by the accumulation of misfolded proteins into affected organs. Amyloid immunoglobulin ligh......
Market Outlook The treatment of type 2 diabetes places a significant...
Market Outlook The treatment of type 2 diabetes places a significant economic burden on the U.S. healthcare system. Given the intense competition among antidiabetic ther......
DRG Epidemiology’s coverage of dyslipidemia comprises epidemiological...
DRG Epidemiology’s coverage of dyslipidemia comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of dyslipidemia for each...
Historically, metformin and the sulfonylureas were the most-prescribed drugs...
Historically, metformin and the sulfonylureas were the most-prescribed drugs for type 2 diabetes. These agents dominated the early lines of therapy until disease progression required insulin repl......
Biguanides and sulfonylureas are by far the most heavily prescribed type 2...
Biguanides and sulfonylureas are by far the most heavily prescribed type 2 diabetes (T2D) drug classes. However, several branded agents are jostling for posit......
Dyslipidemia refers to abnormalities in lipids and lipoproteins in the...
Dyslipidemia refers to abnormalities in lipids and lipoproteins in the circulation and is a key modifiable risk factor for cardiovascular (CV) disease. The mos......
Patients with osteoporosis are at increased risk of fractures owing to the...
Patients with osteoporosis are at increased risk of fractures owing to the loss of bone strength, yet diagnosis and drug-treatment rates for this disease are relatively low. The low treatment rat......
